Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Sanofi-Aventis Joins With TB Drug Alliance
by Ann M. Thayer
October 20, 2008
| A version of this story appeared in
Volume 86, Issue 42
The Global Alliance for TB Drug Development and Sanofi-Aventis will collaborate on the discovery and development of drugs against tuberculosis. They will share information from their separate TB research efforts and discuss regulatory, clinical trial, and drug access strategies related to developing countries. The not-for-profit alliance has two TB drug candidates in clinical trials and 12 others in its pipeline. To support the alliance's work, the U.S. Agency for International Development has just awarded it up to $40 million over the next five years.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter